The FDA approval of daratumumab and hyaluronidase-fihj for high-risk smoldering MM shifts care beyond watchful waiting, notes Peter Voorhees, MD. AQUILA enrolled 390 high-risk patients randomized 1:1 ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal plasma cells accumulate, they crowd out healthy cells and cause symptoms ...

Darzalex Faspro significantly reduced disease progression risk in high-risk smoldering multiple myeloma, with a 51% reduction compared to active monitoring. The AQUILA study showed a median ...

TORONTO -- Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data. With a median follow-up of 3.9 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk ...

What Is Darzalex Faspro, and Why Does It Matter? Darzalex Faspro is a medicine used to treat adults with multiple myeloma, a type of blood cancer, and amyloidosis, a rare condition where abnormal ...

At its June 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the indications for Darzalex (daratumumab) solution for ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as the first-ever treatment for ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. I could not think ...

In 2014, the International Myeloma Working Group (IMWG) updated the diagnostic criteria for multiple myeloma – a change that has had a profound effect on the concept of early treatment of patients ...

Smoldering multiple myeloma is an asymptomatic, precancerous condition with abnormal plasma cells and elevated monoclonal protein levels. Diagnosis involves blood, urine, and bone marrow tests, with ...

New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System This study analyzed next-generation sequencing data from 224 ...